On Friday, Shares of Bed Bath & Beyond Inc. (NASDAQ:BBBY), added 2.20% and closed at $43.11 in the last trading session. The last trading range of the stock ranges between $42.29 and $43.26. Quintiles Transnational Holdings Inc., through its partner, Quintiles Transnational Corp., provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. The companys Product Development segment offers project administration and clinical monitoring services, counting study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, project administration for conducting various multi-site trials, and late phase interventional services; and clinical trial support services comprising clinical data administration, biostatistical, cardiac safety and ECG laboratory, safety and pharmacovigilance, and phase I clinical pharmacology services, in addition to clinical trial, genomic, and bioanalytical laboratory services. This segment also provides planned planning and design services for biomarkers, genomics, and personalized medicine, in addition to offers model-based drug development and regulatory affairs services; and consulting services, such as product development strategy, regulatory and compliance, and process and IT implementation consulting services. Its Integrated Healthcare Services segment offers commercial services comprising contract sales, market entry/market exit, integrated channel administration, patient engagement, and market access and commercialization consulting services; real-world late phase research services, such as observational studies, comparative effectiveness studies, and product and disease registry services; and communication and health engagement services, counting digital patient, and brand and scientific communications services.
3M Co (NYSE:MMM), jumped 0.49% and closed at $176.23 in the last trading session. The last trading range of the stock ranges between $176.09 and $177.15. The company’s Market capitalization is $107.04 Billion with the total Outstanding Shares of 604.40 million. The District Court of Frankfurt, Germany, has ordered a preliminary injunction against China-based Qingdao Summit Industrial Co., Ltd. (“Summit”) for infringement of the German portion of 3M’s European patent EP 0,954,381 B2. This patent relates to 3M’s PPS™ technology that facilitates the efficient mixing and spraying of coatings for automotive collision repair.
The court order prohibits the offer and sale of Summit’s infringing paint spray gun cup sets in Germany with immediate effect and directs Summit to reimburse 3M for its litigation costs. Summit may appeal the court decision to the Upper District Court of Frankfurt.
3M, through its Automotive Aftermarket Division, provides a comprehensive range of products and solutions to the collision repair industry, counting its award-winning PPS™ technology that facilitates painters to mix less paint, reduce the amount of solvent used, and speed cleanup.
3M is committed to protecting its intellectual property and investments in paint spraying technologies.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), remained flat and closed at $1.75 in the last trading session. The last trading range of the stock ranges between $1.72 and $1.80. During the 52-week trading session the minimum price at which share price traded, registered at $1.30 and reached to max level of $2.68. Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases. Its products under development include APD334, a modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which is in Phase II clinical trials; and Ralinepag that is in Phase II clinical trials for the treatment of pulmonary arterial hypertension. The companys products under development also comprise APD371, an agonist of the cannabinoid-2 receptor that is in Phase I clinical trials for the treatment of pain; Nelotanserin, which is in Phase II clinical trials for the treatment of dementia-associated psychosis; Temanogrel, which is in Phase I clinical trials for thrombotic diseases; and Unrevealed Orphan GPCR that is in pre-clinical development for central nervous system indications. In addition, it manufactures drug products under a toll manufacturing agreement for Siegfried AG.